User login
Dr Robert Shin, from Georgetown University Hospital, highlights key presentations in disease-modifying therapy for multiple sclerosis (MS) presented at the 2022 annual meeting of the Consortium of Multiple Sclerosis Centers.
First, Dr Shin discusses BTK inhibitors as an emerging treatment for multiple forms of MS, including progressive MS.
Next, he shares preliminary results from the DISCOMS trial, which studied the safety of discontinuing vs continuing disease-modifying therapy in older MS patients. Although discontinuation was associated with more disease, Dr Shin suggests that a rigorous review of the data reveals no significant difference between the two groups. He comments that more data are needed.
Dr Shin closes his commentary by highlighting a presentation focused on COVID and MS patients, specifically covering immune response to the COVID-19 vaccine in people being treated for MS.
--
Professor, Department of Neurology, MedStar Georgetown University Hospital; Director, Georgetown MS and Neuroimmunology Center, Washington, DC
Robert Shin, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Alexion; Biogen; Bristol Myers Squibb; EMD Serono; Genentech; Horizon; Novartis; Roche; Sanofi Genzyme
Serve(d) as a speaker or a member of a speakers bureau for: Alexion; Biogen; Bristol Myers Squibb; EMD Serono; Genentech; Horizon; Novartis; Roche; Sanofi Genzyme
Dr Robert Shin, from Georgetown University Hospital, highlights key presentations in disease-modifying therapy for multiple sclerosis (MS) presented at the 2022 annual meeting of the Consortium of Multiple Sclerosis Centers.
First, Dr Shin discusses BTK inhibitors as an emerging treatment for multiple forms of MS, including progressive MS.
Next, he shares preliminary results from the DISCOMS trial, which studied the safety of discontinuing vs continuing disease-modifying therapy in older MS patients. Although discontinuation was associated with more disease, Dr Shin suggests that a rigorous review of the data reveals no significant difference between the two groups. He comments that more data are needed.
Dr Shin closes his commentary by highlighting a presentation focused on COVID and MS patients, specifically covering immune response to the COVID-19 vaccine in people being treated for MS.
--
Professor, Department of Neurology, MedStar Georgetown University Hospital; Director, Georgetown MS and Neuroimmunology Center, Washington, DC
Robert Shin, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Alexion; Biogen; Bristol Myers Squibb; EMD Serono; Genentech; Horizon; Novartis; Roche; Sanofi Genzyme
Serve(d) as a speaker or a member of a speakers bureau for: Alexion; Biogen; Bristol Myers Squibb; EMD Serono; Genentech; Horizon; Novartis; Roche; Sanofi Genzyme
Dr Robert Shin, from Georgetown University Hospital, highlights key presentations in disease-modifying therapy for multiple sclerosis (MS) presented at the 2022 annual meeting of the Consortium of Multiple Sclerosis Centers.
First, Dr Shin discusses BTK inhibitors as an emerging treatment for multiple forms of MS, including progressive MS.
Next, he shares preliminary results from the DISCOMS trial, which studied the safety of discontinuing vs continuing disease-modifying therapy in older MS patients. Although discontinuation was associated with more disease, Dr Shin suggests that a rigorous review of the data reveals no significant difference between the two groups. He comments that more data are needed.
Dr Shin closes his commentary by highlighting a presentation focused on COVID and MS patients, specifically covering immune response to the COVID-19 vaccine in people being treated for MS.
--
Professor, Department of Neurology, MedStar Georgetown University Hospital; Director, Georgetown MS and Neuroimmunology Center, Washington, DC
Robert Shin, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Alexion; Biogen; Bristol Myers Squibb; EMD Serono; Genentech; Horizon; Novartis; Roche; Sanofi Genzyme
Serve(d) as a speaker or a member of a speakers bureau for: Alexion; Biogen; Bristol Myers Squibb; EMD Serono; Genentech; Horizon; Novartis; Roche; Sanofi Genzyme
